Chemotherapeutic Agents for Urologic Oncology

  • Hendrik Van Poppel
  • Filip Ameye
Part of the Springer Specialist Surgery Series book series (SPECIALIST)


The main goal of chemotherapy is to cure cancer by killing the neoplastic cells. To keep the cancer from metastasizing, chemotherapy may be used in combination with other cancer treatments, such as surgery and radiotherapy. In widespread, fast-growing cancers, chemotherapy reduces cellular proliferation, eases symptoms, and improves the quality of life. When it is employed after the primary tumor has been treated by some other modality, it is called adjuvant chemotherapy. Sometimes neoadjuvant chemotherapy is employed, which refers to the initial use of chemotherapy in patients with localized cancer in order to reduce tumor burden, there by rendering local therapy (surgery or radiotherapy) more effective. A common procedure in human cancer therapy is combination chemotherapy that refers to the parallel or sequential use of several different antineoplastic agents in order to enhance their effectiveness. Combining chemotherapy with targeted therapies is an investigational approach under development. This chapter presents a comprehensive overview of the use of chemotherapeutics and targeted agents in the treatment of urologic malignancies.


Bladder Cancer Radical Cystectomy Testicular Cancer Penile Cancer Hormone Refractory Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171:2186-2190PubMedCrossRefGoogle Scholar
  2. 2.
    Babjuk M, Oosterlinck W, Sylvester RJ, Kaasinen E, Böhle A, Palou J. Guidelines on TaT1 non-muscle invasive bladder cancer. European Association of Urology. 2008. Accessed September 17, 2008
  3. 3.
    Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466-477PubMedCrossRefGoogle Scholar
  4. 4.
    Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol. 1996;156:1934-1941PubMedCrossRefGoogle Scholar
  5. 5.
    Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol. 2000;53:676-680PubMedCrossRefGoogle Scholar
  6. 6.
    Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001;21:765-769PubMedGoogle Scholar
  7. 7.
    Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008;53:709-719PubMedCrossRefGoogle Scholar
  8. 8.
    Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006;24:296-304PubMedCrossRefGoogle Scholar
  9. 9.
    Stenzl A, Cowan NC, De Santis M, et al. Guidelines on bladder cancer; muscle-invasive and metastatic. Eur AssocUrol. 2008. Accessed September 17, 2008
  10. 10.
    Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361: 1927-1934CrossRefGoogle Scholar
  11. 11.
    Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004;171:561-569PubMedCrossRefGoogle Scholar
  12. 12.
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202-206CrossRefGoogle Scholar
  13. 13.
    Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20:3061-3071PubMedCrossRefGoogle Scholar
  14. 14.
    Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988;139:461-469PubMedGoogle Scholar
  15. 15.
    Sternberg CN, Yagoda A, Scher H, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989;64: 2448-2458PubMedCrossRefGoogle Scholar
  16. 16.
    von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077PubMedGoogle Scholar
  17. 17.
    Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol. 2003;46(suppl): S105-115PubMedCrossRefGoogle Scholar
  18. 18.
    Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42:50-54PubMedCrossRefGoogle Scholar
  19. 19.
    Gallagher DJ, Milowsky MI, Bajorin DF. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer. 2008;113:1284-1293PubMedCrossRefGoogle Scholar
  20. 20.
    Heidenreich A, Aus G, Abbou CC, et al. Guidelines on prostate cancer. Eur Urol. 2007. Accessed September 17, 2008
  21. 21.
    Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512PubMedCrossRefGoogle Scholar
  22. 22.
    Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520PubMedCrossRefGoogle Scholar
  23. 23.
    Calabro F, Sternberg CN. Current indications for chemotherapy in prostate cancer patients. Eur Urol. 2007;51:17-26PubMedCrossRefGoogle Scholar
  24. 24.
    Berthold DR, Pond G, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival of the TAX 327 study. J Clin Oncol Suppl. 2007; 25:5005Google Scholar
  25. 25.
    de Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int. 2008;101(suppl 2):11-15PubMedCrossRefGoogle Scholar
  26. 26.
    Lin AM, Ryan CJ, Small EJ. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol. 2007;61:243-254PubMedCrossRefGoogle Scholar
  27. 27.
    Oh WK, Tay MH, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer. 2007;109: 477-486PubMedCrossRefGoogle Scholar
  28. 28.
    de Kernion JB, Lee AK, Vogelzang NJ. Treatment of organ-confined, locally advanced and metastatic prostate cancer. American Urological Association (AUA) Annual Meeting Highlights; May 19–24, 2007; 7–9. Anaheim, CA. Accessed September 22, 2008
  29. 29.
    Di Lorenzo G, Autorino R, De Laurentiis M, et al. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther. 2007;6:313-317PubMedCrossRefGoogle Scholar
  30. 30.
    Ljungberg B, Hanbury DC, Kuczyk MA, et al. Guidelines on renal cell carcinoma. Eur Assoc Urol. 2007;51:1502–10 Accessed September 25, 2008Google Scholar
  31. 31.
    Schrader AJ, Varga Z, Hegele A, Pfoertner S, Olbert P, Hofmann R. Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol. 2006;132:137-149PubMedCrossRefGoogle Scholar
  32. 32.
    Vakkalanka BK et al. Targeted therapy in renal cell carcinoma. Curr Opin Urol. 2008;8(5):481-487CrossRefGoogle Scholar
  33. 33.
    Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111PubMedCrossRefGoogle Scholar
  34. 34.
    Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha monotherapy in metastatic renal cell carcinoma [abstract 350]. In: Genitourinary cancers symposium; February 14–16, 2008; San Francisco: AM Soc Clinl Oncol, 2008Google Scholar
  35. 35.
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124PubMedCrossRefGoogle Scholar
  36. 36.
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134PubMedCrossRefGoogle Scholar
  37. 37.
    Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281PubMedCrossRefGoogle Scholar
  38. 38.
    Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456PubMedCrossRefGoogle Scholar
  39. 39.
    Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part I. Eur Urol. 2008;53:478-496PubMedCrossRefGoogle Scholar
  40. 40.
    Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008;53:497-513PubMedCrossRefGoogle Scholar
  41. 41.
    Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005;366: 293-300PubMedCrossRefGoogle Scholar
  42. 42.
    Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer. EurAssoc Urol. 2008. Accessed September 26, 2008
  43. 43.
    International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15: 594–603Google Scholar
  44. 44.
    Solsona E, Algaba F, Horenblas S, Pizzocaro G, Windahl T. Guidelines on penile cancer. Euro Assoc Urol. 2008;54: 631–639 Accessed September 29, 2008Google Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  • Hendrik Van Poppel
    • 1
  • Filip Ameye
    • 2
  1. 1.Department of UrologyUniversity Hospitals Leuven, Campus GasthuisbergLeuvenBelgium
  2. 2.University of Hospital Gasthuisberg, Katholieke Universiteit LeuvenLeuvenBelgium

Personalised recommendations